Payment overview · 2025
General Payments
$714.28
13 reported records · 10 companies
Healthcare provider profile · identity verified
Mary Morris, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · LA FOLLETTE, TN · NPI 1639143258
Verified facts
What the public records show
CMS Open Payments records show Mary Morris, CFNP received $714.28 in general payments during 2025 across 13 reported records.
Corcept Therapeutics accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $143.93 | 20.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.82 | 17.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $110.95 | 15.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.16 | 14.3% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $99.48 | 13.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.69 | 5.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.75 | 4.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.47 | 3.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.06 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.97 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.28 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $143.93 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $110.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.16 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $99.48 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.75 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 103 |
| Lisinopril | Lisinopril | 379 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 59 |
| Omeprazole | Omeprazole | 174 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 53 |
| Potassium Chloride | Potassium Chloride | 158 | 49 |
| Metformin Hcl | Metformin Hcl | 155 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 39 |
| Famotidine | Famotidine | 106 | 33 |
| Jardiance | Empagliflozin | 105 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 24 |
| Gabapentin | Gabapentin | 93 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 19 |
| Losartan Potassium | Losartan Potassium | 84 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Metformin Hcl Er | Metformin Hcl | 78 | 22 |
| Trazodone Hcl | Trazodone Hcl | 77 | 28 |
| Eliquis | Apixaban | 72 | 18 |
| Buspirone Hcl | Buspirone Hcl | 61 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 17 |
| Ozempic | Semaglutide | 57 | 16 |
| Farxiga | Dapagliflozin Propanediol | 54 | 16 |
| Furosemide | Furosemide | 54 | 20 |
| Montelukast Sodium | Montelukast Sodium | 52 | 13 |
| Simvastatin | Simvastatin | 50 | 12 |
| Sertraline Hcl | Sertraline Hcl | 49 | 16 |
| Carvedilol | Carvedilol | 48 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 47 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 12 |
| Mirtazapine | Mirtazapine | 40 | 15 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 30 |
| Glyxambi | Empagliflozin/Linagliptin | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Ramipril | Ramipril | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.28 · 13 records | Corcept Therapeutics | CeQur Simplicity, FREESTYLE LIBRE 3, ID NOW INSTRUMENT, Kerendia, Korlym, LEQVIO, Ozempic, RECORLEV, TWIIST, The Cologuard Plus Collection Kit, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error